2-((4-(Carboxymethyl)phenoxy)methyl)benzoic acid

We are 2-((4-(Carboxymethyl)phenoxy)methyl)benzoic acid CAS:55453-89-9 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:2-((4-(Carboxymethyl)phenoxy)methyl)benzoic acid
CAS.NO:55453-89-9
Synonyms:2-((4-(Carboxymethyl)phenoxy)methyl)benzoic acid
Acetic 2-(phenoxymethyl)benzoic anhydride
 
Physical and Chemical Properties:
Density 1.2±0.1 g/cm3
Boiling Point 435.8±37.0 °C at 760 mmHg
Molecular Formula C16H14O4
Molecular Weight 270.280
Flash Point 194.4±26.5 °C
 
Specification:
Appearance:Light yellow powder
Assay:≥98.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate of Olopatadine(CAS:113806-05-6).

2-((4-(Carboxymethyl)phenoxy)methyl)benzoic acid


Related News: It is frequently associated with the presence of blasts or leukemic cells in the marrow.ethyl 4-methoxy-3-oxobutanoate In an August overhaul to its drug administration law, Beijing said conditional approval could be granted to some still-under-research medicines of “predictable” clinical value for life-threatening diseases for which effective treatment is not immediately available.1-Methyl-1,2,3,6-Tetrahydropyridine Hydrochloride In an August overhaul to its drug administration law, Beijing said conditional approval could be granted to some still-under-research medicines of “predictable” clinical value for life-threatening diseases for which effective treatment is not immediately available.Nonanedioato de dimetilo CAS:1732-10-1 The intravenous form of rigosertib has been studied in Phase 1, 2, and 3 clinical trials involving more than 1000 patients, and is currently being evaluated in a randomized Phase 3 international INSPIRE trial for patients with HR-MDS after failure of HMA therapy.The intravenous form of rigosertib has been studied in Phase 1, 2, and 3 clinical trials involving more than 1000 patients, and is currently being evaluated in a randomized Phase 3 international INSPIRE trial for patients with HR-MDS after failure of HMA therapy.

Related Products
Product Name
4-Bromo-3,5-dimethylphenol View Details
Antide View Details
3,5-Dichloro-2,4-difluoroaniline View Details
3-Nitrobenzotrifluoride manufacturer 4-Hydroxyphenyl hydantoin manufacturer 4-Methylpyridin-2-amine manufacturer 3-Fluoro-4-methoxybenzonitrile manufacturer 5-Bromo-2-chloro-4-methylpyridine manufacturer